Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Z6AX
|
|||
Former ID |
DIB003686
|
|||
Drug Name |
BAY-27-9955
|
|||
Synonyms |
Glucagon antagonists, Bayer
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Discontinued in Phase 1 | [1], [2] | |
Company |
Bayer AG
|
|||
Structure |
Download2D MOL |
|||
Formula |
C23H31FO
|
|||
Canonical SMILES |
CCCC1=C(C(=C(C=C1C(C)C)C(C)C)C(C)O)C2=CC=C(C=C2)F
|
|||
InChI |
1S/C23H31FO/c1-7-8-19-20(14(2)3)13-21(15(4)5)22(16(6)25)23(19)17-9-11-18(24)12-10-17/h9-16,25H,7-8H2,1-6H3
|
|||
InChIKey |
VDTWKXAPIQBOMO-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 202855-56-9
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon receptor (GCGR) | Target Info | Antagonist | [3] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Glucagon signaling pathway | ||||
Reactome | Glucagon signaling in metabolic regulation | |||
G alpha (q) signalling events | ||||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3491). | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013061) | |||
REF 3 | Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001 Nov;44(11):2018-24. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.